DGAP-Adhoc: MOLOGEN AG: Change within the Supervisory Board - Chairman resigns due to health reasons as announced - successor nominated.

        Print
| Source: EQS Group AG
MOLOGEN AG  / Key word(s): Change of Personnel

01.07.2013 15:04

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

MOLOGEN AG: Change within the Supervisory Board - Chairman resigns due to
health reasons as announced - successor nominated.

Berlin, July 1, 2013 - Dr. Mathias P. Schlichting, member and chairman of
the Supervisory Board of MOLOGEN AG, resigned from office today due to
health reasons as previously announced. After co-ordination with the
remaining members of the Supervisory Board the Executive Board has decided
today to nominate Stefan ten Doornkaat, independent lawyer, Düsseldorf, as
successor for a term lasting until the ordinary annual general meeting in
2014. The application for the judicial appointment will be filed today.
After the appointment the remaining members of the Supervisory Board and Mr
ten Doornkaat intend to elect Gregor Kunz as the new Chairman of the
Supervisory Board.


---------------------------------------------------------------------------

Information and Explaination of the Issuer to this News:

'First of all we especially thank Dr. Mathias P. Schlichting for his
commitment over many years and his fruitful work for MOLOGEN AG. He has
advised the company critically and professionally from the very beginning
and supported a large number of decisions that significantly contributed to
the successful development of the company. Furthermore we are very thankful
that he enabled a smooth transition and above all we wish him a good
recovery. At the same time we are glad to have won Stefan ten Doornkaat as
new member of the Supervisory Board in short notice. With his extensive
professional experience as lawyer especially in the field of capital
markets and tax he contributes important skills and directly fills the
functional gap', says Dr. Matthias Schroff, CEO of MOLOGEN AG

About MOLOGEN AG 
MOLOGEN AG is a publicly listed biotechnology company headquartered in
Berlin and specializes in the research and clinical development of
innovative drugs in the fields of oncology and infectious diseases. One of
the company's most important product candidates is the DNA immunomodulator
MGN1703, which is being clinically developed for colorectal cancer and lung
cancer. The cell-based cancer therapy MGN1601 for the treatment of renal
cancer is also currently at the stage of clinical development.

With
unique, patented technologies and innovative product developments, MOLOGEN
is one of the leading biotechnology companies in the fields of DNA medicine
and cell-based therapies.

MOLOGEN AG shares (ISIN DE0006637200) are listed
in the Prime Standard of the German Stock Exchange.

www.mologen.com 

Memberships in associations:
Biotechnologieverbund Berlin-Brandenburg (bbb) e.V. | BIO Deutschland e.V. 
|  DECHEMA - Society for chemical technology and biotechnology e.V.  | 
German industrial association of biotechnology (DIB)  |  Association for
the Promotion of Science and Humanities in Germany  |  Association of
German biotechnology companies (VBU)  |  Association of researching
manufacturers of pharmaceuticals e.V. (VFA)  |  Association of the chemical
industry e.V. (VCI)

MIDGE(R), dSLIM(R) and MOLOGEN(R) are registered trademarks of MOLOGEN AG.

MOLOGEN AG

PRESS SERVICE:
Prof. Peter W. Hübner
Head of Corporate Communications
Tel: +49 - 30 - 84 17 88 - 38
Fax: +49 - 30 - 84 17 88 - 50
huebner@mologen.com

INVESTOR RELATIONS:
Jörg Petraß
Tel: +49 - 30 - 84 17 88 - 13
Fax: +49 - 30 - 84 17 88 - 50
investor@mologen.com 

External Investor Relations:
Kirchhoff Consult AG
Sebastian Bucher
Tel: +49 - 40 - 60 91 86 - 18
Fax: +49 - 40 - 60 91 86 - 16
sebastian.bucher@kirchhoff.de 

Note about risk for future predictions
Certain information in this report contains forward-looking statements or
the corresponding statements with negation or versions deviating from this
or comparable terminology. These are described as forward-looking
statements. In addition, all of the information given here that refers to
planned or future results of business areas, key financial figures,
developments of the financial situation or other financial figures or
statistical data, is to be understood as such forward-looking statements.
The company points out to investors that they should not rely on these
forward-looking statements as predictions about actual future events. The
company is not obligated and refuses to accept any liability for the
forward-looking statements and has no obligation to update such statements
in order to accurately reflect the current situation.

01.07.2013 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------
 
Language:     English
Company:      MOLOGEN AG
              Fabeckstraße 30
              14195 Berlin
              Germany
Phone:        030 / 841788-0
Fax:          030 / 841788-50
E-mail:       info@mologen.com
Internet:     www.mologen.com
ISIN:         DE0006637200
WKN:          663720
Listed:       Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
              in Berlin, Düsseldorf, Hamburg, München, Stuttgart
 
End of Announcement                             DGAP News-Service
 
---------------------------------------------------------------------------